SCHEMBL4624601

SCHEMBL4624601

Oc1cccc2ccc(Oc3c(Cl)cccc3Cl)nc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.48
NPC1 O15118 6/20 0.48
MEN1 O00255 6/20 0.48
HSP90AA1 P07900 2/20 0.48
AGTR1 P30556 1/20 0.48
METAP2 P50579 2/20 0.46
PLAU P00749 1/20 0.46
NCF1 P14598 1/20 0.46
RAB9A P51151 4/20 0.46
KDM4E B2RXH2 3/20 0.46
MAPT P10636 3/20 0.46
HTT P42858 2/20 0.46
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
HPGD P15428 1/20 0.45
ALOX12 P18054 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3227590 0.84 METAP2 (0.57) KMT2ANPC1MEN1AGTR1METAP2
SCHEMBL4626479 0.79 ALDH1A1 (0.47) KMT2ANPC1MEN1HSP90AA1AGTR1
SCHEMBL4626576 0.78 MEN1 (0.56) KMT2ANPC1MEN1AGTR1METAP2
SCHEMBL4619472 0.77 METAP2 (0.50) KMT2ANPC1MEN1HSP90AA1AGTR1
SCHEMBL4624293 0.77 KDM4E (0.49) KMT2ANPC1MEN1HSP90AA1AGTR1
SCHEMBL1043719 0.74 METAP2 (0.58) KMT2ANPC1MEN1HSP90AA1AGTR1
SCHEMBL30457998 0.73 METAP2 (0.56) KMT2ANPC1MEN1HSP90AA1AGTR1
SCHEMBL31157799 0.73 METAP2 (0.56) KMT2ANPC1MEN1HSP90AA1AGTR1
SCHEMBL29040602 0.73 METAP2 (0.56) KMT2ANPC1MEN1HSP90AA1AGTR1
SCHEMBL11817511 0.73 KDM4E (0.56) KMT2ANPC1MEN1METAP2PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501801-B1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES UCB PHARMA SA (BE) 2008-01-23 EP claimed